Physician resources for MYCAPSSA® (octreotide)

Resources

MYCAPSSA Brochure

If you want to take the next step in learning more about MYCAPSSA, download this helpful brochure.

READ MORE

CAPS Program Overview

Discover the one-on-one support you and your patients get with the Chiasma Access and Patient Support Program (CAPS).

READ MORE

Patient Enrollment Form

Complete the simple enrollment form to initiate the process for getting your patient started on MYCAPSSA.

SUBMIT ONLINE FORM DOWNLOAD FORM

Patient Communication Tools

Inform your patients about the availability and key benefits of MYCAPSSA treatment with quick, convenient letter and email guides that can be customized to your office and patients.

Download Now

Maintenance of Acromegaly Control in Patients Switching from Injectable Somatostatin Receptor Ligands to Oral Octreotide

READ MORE

Analysis of adverse events in adult patients with acromegaly receiving oral octreotide capsules: results from the phase 3, randomized, double-blind, placebo-controlled CHIASMA OPTIMAL study

READ MORE

Transient Permeability Enhancer® (TPE) Technology

MYCAPSSA offers oral delivery of octreotide, made possible by Transient Permeability Enhancer, TPE®, Technology. This oral octreotide delivery can help patients overcome the burden and challenges associated with injectable SSA administration, such as pain and injection site reactions.2

see TPE technology in action

MYCAPSSA® Virtual Rep Detail

As the first and only FDA-approved oral SSA for appropriate patients, MYCAPSSA represents an exciting and significant advancement in the treatment of acromegaly by freeing patients from the burden of SSA injections.2 In the pivotal trial, the majority of patients who switched to MYCAPSSA twice daily from injectable SSAs experienced consistent biochemical control with mean IGF-I levels maintained within the normal range during the 9-month trial period.3 Learn more about MYCAPSSA, the TPE technology that powers it, and the efficacy and safety studies supporting MYCAPSSA in appropriate patients in this virtual rep detail.

Watch Now

Understanding the Management of Acromegaly with MYCAPSSA® (octreotide) Delayed-Release Oral Capsules

Hear Dr. Anthony Heaney, MD, PhD, Professor at David Geffen School of Medicine, University of California Los Angeles (UCLA), discuss the first oral treatment option for appropriate patients with acromegaly.

Watch Now

A Nursing Perspective: Understanding MYCAPSSA and Available Resources

Join Daphne Adelman, BSN, MBA Clinical Nurse Specialist with Chiasma as she shares an overview of the MYCAPSSA phase 3 clinical trials and safety profile, discusses how to get appropriate patients with acromegaly started on therapy and highlights the dosing and storage information for MYCAPSSA.

Watch Now

What MYCAPSSA® (octreotide) Delayed-Release Oral Capsules Approval Means to the Acromegaly Patient Community

Learn from Jill Sisco, President of Acromegaly Community, what the value of an oral SSA treatment option offers patients and what MYCAPSSA could mean for patients with acromegaly.

Watch Now

ADDITIONAL VIDEOS

Click here to watch more videos and patient experiences with acromegaly.

Sign up now

Learn more about how MYCAPSSA is changing acromegaly treatment.

   

*Required Field

 

By clicking ‘Submit,’ I agree to receive communications from Chiasma, Inc., and I understand that my information will be used in accordance with the Chiasma, Inc. Privacy Policy.

READ MORE  

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE
MYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

CONTRAINDICATIONS
Hypersensitivity to octreotide or any of the components of MYCAPSSA. Anaphylactoid reactions, including anaphylactic shock, have been reported in patients receiving octreotide.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS
MYCAPSSA can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected.

Blood sugar, thyroid levels, and vitamin B12 levels should be monitored and treated accordingly.

Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted.

ADVERSE REACTIONS
The most common adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis.

DRUG INTERACTIONS
The following drugs require monitoring and possible dose adjustment when used with MYCAPSSA: cyclosporine, insulin, antidiabetic drugs, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and drugs mainly metabolized by CYP3A4. Counsel women to use an alternative non-hormonal method of contraception or a back-up method when MYCAPSSA is used with combined oral contraceptives.

Patients taking proton pump inhibitors, H2-receptor antagonists, or antacids concomitantly with MYCAPSSA may require increased dosages of MYCAPSSA.

PREGNANCY
Advise premenopausal females of the potential for an unintended pregnancy.

To report SUSPECTED ADVERSE REACTIONS, contact the product information department at 1-844-312-2462 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

READ MORE  

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE
MYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

CONTRAINDICATIONS
Hypersensitivity to octreotide or any of the components of MYCAPSSA. Anaphylactoid reactions, including anaphylactic shock, have been reported in patients receiving octreotide.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS
MYCAPSSA can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected.

Blood sugar, thyroid levels, and vitamin B12 levels should be monitored and treated accordingly.

Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted.

ADVERSE REACTIONS
The most common adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis.

DRUG INTERACTIONS
The following drugs require monitoring and possible dose adjustment when used with MYCAPSSA: cyclosporine, insulin, antidiabetic drugs, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and drugs mainly metabolized by CYP3A4. Counsel women to use an alternative non-hormonal method of contraception or a back-up method when MYCAPSSA is used with combined oral contraceptives.

Patients taking proton pump inhibitors, H2-receptor antagonists, or antacids concomitantly with MYCAPSSA may require increased dosages of MYCAPSSA.

PREGNANCY
Advise premenopausal females of the potential for an unintended pregnancy.

To report SUSPECTED ADVERSE REACTIONS, contact the product information department at 1-844-312-2462 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

REFERENCES

1. Colao A, et al. Nat Rev Dis Primers 2019;5(1):20. 2. MYCAPSSA. Prescribing information. Chiasma, Inc.;2020. 3. Samson SL, et al. J Clin Endocrinol Metab. 2020;105(10):dgaa526. 4. Melmed S, et al. J Clin Endocrinol Metab. 2015;100(4):1699-1708. 5. Geer EB, et al. Pituitary. 2020. https://doi.org/10.1007/s11102-019-01013-2 6. Strasburger CJ, et al. Eur J Endocrinol. 2016;174(3):355-362. 7. Karsdal MA, et al. Br J Clin Pharmacol. 2015;79(5):720-732. 8. Data on file. Chiasma, Inc.